ISRCTN12307286
Active, not recruiting
未知
Randomised, multi-centre study to assess efficacy, tolerability and safety of Enterosgel® in the treatment of acute atopic dermatitis in adults
Enteromed Ltd0 sites44 target enrollmentFebruary 8, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Atopic dermatitis
- Sponsor
- Enteromed Ltd
- Enrollment
- 44
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Has acute manifestations of dermatitis at the time of screening
- •2\. Has a diagnosis of dermatitis evidenced by a read code (list of read codes provided in the protocol)
- •3\. Aged 18 to 60
- •4\. Able to give informed consent and complete the required study procedures, including providing a blood sample
- •5\. Considered suitable to take part in the study in GP's opinion
Exclusion Criteria
- •1\. History of intestinal atony (severe constipation due to bowel obstruction)
- •2\. Fever (\> 39 degrees Celsius)
- •3\. Any other clinically significant skin condition in GP's opinion
- •4\. A history of clinically significant allergic reactions in GP's opinion
- •5\. Use of any clinical trial investigational medication or medical devices within the last 30 days before screening visit
- •6\. Patients with known cancer of any localisation
- •7\. Any underlying condition that could affect the patient’s participation in this study or the results of this study in GP's opinion
- •8\. Pregnancy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs a tacrolimus-based control regimen in de novo liver transplant recipients - NDde novo liver transplant recipientsMedDRA version: 9.1Level: LLTClassification code 10024714Term: Liver transplantEUCTR2007-001776-36-ITOVARTIS FARMA320
Active, not recruiting
Phase 1
A randomized multicenter study evaluating efficacy, safety, tolerability and pharmacokinetics of AEB071 combined with tacrolimus or mycophenolate mofetil (MMF) vs. a tacrolimus-based control regimen in de novo liver transplant recipients.EUCTR2007-001776-36-GBovartis Pharma Services AG
Recruiting
Not Applicable
Home-based and group cognitive intervention programs in amnestic mild cognitive impairmentMental and behavioral disordersKCT0000328Inha University Hospital270
Active, not recruiting
Not Applicable
Multicenter randomized study to assess the efficacy and the safety of two therapeutic regimens(high dose of imiglucerase versus co-administration of imiglucerase and miglustat) in type I Gaucher disease patients who have not responded to previous treatment with low dose imiglucerase - NDGAUCHER diseaseMedDRA version: 9.1Level: LLTClassification code 10018048Term: Gaucher's diseaseEUCTR2007-005516-61-ITISTITUTO GIANNINA GASLINI
Active, not recruiting
Phase 1
A randomized, multi-center study to assess the effect of Darbepoetin alfa (Aranesp®) for the treatment of anemia in patients with advanced hormone independent prostate cancer and anaemia - DANCAPepoIn an open randomised, multi-center study to identify the haematopoietic response to Aranesp® (Darbepoetin 6,75 mcg/kg) administrated every fourth week compared to standard care of treatment in patients with anaemia due to hormone refractory prostate cancer with progression of skeletal metastases. A haematopoietic response is defined as haemoglobin concentration > 12 g/dl or increase in haemoglobin > 2 g/dl during the treatment phase.MedDRA version: 6.1Level: PTClassification code 10038444EUCTR2005-005658-37-DKDpt. of Urology -K. Aarhus University Hospital140